Table 1.
Clinical and biological features of the primary B-ALL samples used in this study
| Sample | Molecular | Disease stage | Blasts, % | Age, years | Gender | CD19 MFI | CD22 MFI |
|---|---|---|---|---|---|---|---|
| Pt#1 | ETV6/RUNX1 | diagnosis | 90 | 12 | female | 9,749 | 3,848 |
| Pt#2 | ETV6/RUNX1 | diagnosis | 96 | 5 | male | 22,826 | 7,570 |
| Pt#3 | ETV6/RUNX1 | diagnosis | 97 | 2 | male | 12,104 | 3,581 |
| Pt#4 | NUP214-ABL1 | diagnosis | 95 | 24 | male | + | + |
| Pt#5 | PAX5-MLLT3 | relapse after CD19-CAR T cell therapy and alloSCT | 92 | 31 | male | − | + |
| PDX#1 | high-hyperdiploid | relapse | 97 | 3.5 | male | 14,963 | 7,881 |
| PDX#2 | low-hypodiploid | diagnosis | 97 | 12 | male | 25,459 | 15,192 |
| PDX#3 | TCF3-PBX1 | diagnosis | 98 | 7 | female | 4,510 | 2,028 |
| PDX#4 | high-hyperdiploid | diagnosis | 92 | 2.5 | male | 15,554 | 6,167 |
alloSCT, allogenic stem cell transplantation; MFI, mean fluorescence intensity.